1.75
-0.01(-0.57%)
Currency In USD
| Previous Close | 1.76 |
| Open | 1.76 |
| Day High | 1.81 |
| Day Low | 1.72 |
| 52-Week High | 3.19 |
| 52-Week Low | 1.13 |
| Volume | 767,515 |
| Average Volume | 382,680 |
| Market Cap | 62.91M |
| PE | -2.97 |
| EPS | -0.59 |
| Moving Average 50 Days | 1.69 |
| Moving Average 200 Days | 1.9 |
| Change | -0.01 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $143.44 as of September 09, 2025 at a share price of $1.75. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $451.03 as of September 09, 2025 at a share price of $1.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) met recently and recommended to continue the study w
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
GlobeNewswire Inc.
Jul 24, 2025 12:53 PM GMT
BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next-generation of allosteric small molecule the
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
GlobeNewswire Inc.
Jul 16, 2025 1:03 PM GMT
BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the